Clean Version of Amended Claims

Pursuant to 37 C.F.R. § 1.121(c)(1)(ii)

26. (Amended) A dosage formulation comprising an effective amount of human or humanized monoclonal antibodies, the antibodies consisting of antibodies neutralizing Shiga like toxin II *in vivo*, to prevent or treat hemolytic uremic syndrome in a human.

27. The dosage formulation of claim 26, wherein the antibodies are human monoclonal antibodies.

28. The dosage formulation of claim 26, wherein the antibodies are produced by recombinant DNA methodology.

29. The dosage formulation of claim 26, wherein the antibodies are chimeric monoclonal antibodies.

30. The dosage formulation of claim 26, wherein the antibodies bind to the alpha subunit of the Shiga like toxin II.

31. (Amended) The dosage formulation of claim 26 wherein the antibodies are effective to prevent neurological signs of hemolytic uremic syndrome or lesions, wherein the neurological signs or lesions are selected from the group consisting of bloody diarrhea, acute renal failure, cerebral hemorrhaging, bacterial shedding into feces, bacterial lesions, paddling, head-pressing, ataxia, convulsions and wasting.

32. The dosage formulation of claim 26, wherein the antibodies are effective to prolong survival.

33. The dosage formulation of claim 26, in a pharmaceutically acceptable carrier for injection.

34. The dosage formulation of claim 26 equivalent to 4 ml serum from an animal immunized with Shiga-like toxin II/kg body weight.

35. (Amended) The dosage formulation of claim 26 producing a serum level of anti-Shiga toxin II antibodies of at least [about] 0.5 micrograms/ml.

36. The dosage formulation of claim 26 equivalent to a dosage of 3 mg human monoclonal antibody to Shiga-like toxin II administered to a newborn pig.